Morgan Stanley Targets $93 on CG Oncology After Early Phase 3 Enrollment and Rolling BLA
Morgan Stanley set a $93 price target for CG Oncology, implying 71.6% upside from its $54.20 following a 'Strong Buy' rating on its bladder cancer pipeline. Enrollment in the Phase 3 PIVOT-006 trial completed early and rolling BLA for cretostimogene in high-risk NMIBC awaits FDA acceptance ahead of mid-2026 topline data.
1. Morgan Stanley Sets Bullish Price Target and Rating
On January 9, 2026, Morgan Stanley established a $93 price target for CG Oncology, implying upside of approximately 71.6% from its prevailing share level. The firm assigned a "Strong Buy" rating, citing the company’s advancing clinical pipeline and a series of near-term catalysts focused on bladder cancer therapies.
2. Rapid Progress in Phase 3 PIVOT-006 Trial
CG Oncology announced early completion of patient enrollment in its Phase 3 PIVOT-006 study evaluating cretostimogene in intermediate-risk non–muscle-invasive bladder cancer. This milestone accelerates the timetable for topline data, now anticipated in the first half of 2026, positioning the company for its initial pivotal readout in this indication.
3. Rolling BLA Submission and FDA Alignment
The company has initiated a rolling Biologics License Application for cretostimogene, targeting high-risk BCG-unresponsive non–muscle-invasive bladder cancer. CG Oncology reports constructive feedback from the FDA on trial endpoints and manufacturing controls, making FDA acceptance of the BLA a key near-term catalyst.
4. Solid Capital Structure and Liquidity Profile
CG Oncology currently maintains a market capitalization of about $4.06 billion and reported average daily trading volume near 7 million shares. The firm ended 2025 with approximately $400 million in cash and equivalents, providing runway through multiple clinical readouts and regulatory milestones scheduled over the next 12–18 months.